{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T14:06:10Z","timestamp":1708005970005},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"DOI":"10.7759\/cureus.30552","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T15:54:55Z","timestamp":1666367695000},"source":"Crossref","is-referenced-by-count":1,"title":["Septic Shock Due to Urinary Tract Infection in an Immunosuppressed Patient Prescribed Dapagliflozin"],"prefix":"10.7759","author":[{"given":"Yuto","family":"Suetani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Arita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif ME","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al.. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021, 27:1954-60. 10.1038\/s41591-021-01536-x","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu WT","year":"2015","unstructured":"Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015, 38:1218-27. 10.2337\/dc14-0315","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter LA","year":"2014","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014, 62:1252-62. 10.1111\/jgs.12881","journal-title":"J Am Geriatr Soc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan JR","year":"2019","unstructured":"Donnan JR, Grandy CA, Chibrikov E, et al.. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019, 9:e022577. 10.1136\/bmjopen-2018-022577","journal-title":"BMJ Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109816","article-title":"Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: a retrospective cohort study","volume":"186","author":"Lin YH","year":"2022","unstructured":"Lin YH, Lin CH, Huang YY, Tai AS, Fu SC, Chen ST, Lin SH. Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: a retrospective cohort study. Diabetes Res Clin Pract. 2022, 186:109816. 10.1016\/j.diabres.2022.109816","journal-title":"Diabetes Res Clin Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3310\/hta21020","article-title":"Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation","volume":"21","author":"Johnston R","year":"2017","unstructured":"Johnston R, Uthman O, Cummins E, et al.. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017, 21:1-218. 10.3310\/hta21020","journal-title":"Health Technol Assess"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21720","article-title":"Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin","volume":"14","author":"Khan S","year":"2022","unstructured":"Khan S, Hashmi MS, Rana MA, Zafar GM, Asif S, Farooq MT, Zahoor S. Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin. Cureus. 2022, 14:e21720. 10.7759\/cureus.21720","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46039-5","article-title":"Associated clinical factors for serious infections in patients with systemic lupus erythematosus","volume":"9","author":"Jung JY","year":"2019","unstructured":"Jung JY, Yoon D, Choi Y, Kim HA, Suh CH. Associated clinical factors for serious infections in patients with systemic lupus erythematosus. Sci Rep. 2019, 9:9704. 10.1038\/s41598-019-46039-5","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/118983-septic-shock-due-to-urinary-tract-infection-in-an-immunosuppressed-patient-prescribed-dapagliflozin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:30Z","timestamp":1707508290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/118983-septic-shock-due-to-urinary-tract-infection-in-an-immunosuppressed-patient-prescribed-dapagliflozin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.30552","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}